Drugs that treat a form of vision loss known as age related macular degeneration aren’t just big business. They’re also a controversial part of the national debate over high drug prices, and their increased use has put ophthalmologists in the crosshairs of insurers, the federal government, and the press.
“Retina practices are under significantly increased scrutiny relative to even two or three years ago,” says W. Lloyd Clark, a retina specialist at Palmetto Retina Center in West Columbia, SC. “The amount of attention is substantially higher.”
